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Resistance to cytotoxic chemotherapy drugs, in-
cluding doxorubicin, is a significant obstacle to the
effective treatment of breast cancer. Here, we have
identified a mechanism by which the PI3K/Akt
pathway mediates resistance to doxorubicin. In addi-
tion to inducing DNA damage, doxorubicin triggers
sustained activation of Akt signaling in breast cancer
cells. We show that Akt contributes to chemotherapy
resistance such that PI3K or Akt inhibitors sensitize
cells to doxorubicin. We identify MERIT40, a compo-
nent of the BRCA1-A DNA damage repair complex,
as an Akt substrate that is phosphorylated following
doxorubicin treatment. MERIT40 phosphorylation
facilitates assembly of the BRCA1-A complex in res-
ponse to DNA damage and contributes to DNA
repair and cell survival following doxorubicin treat-
ment. Finally, MERIT40 phosphorylation in human
breast cancers is associated with estrogen receptor
positivity. Our findings suggest that combination
therapy with PI3K or Akt inhibitors and doxorubicin
may constitute a successful strategy for overcoming
chemotherapy resistance.INTRODUCTION
As a component of both monotherapy and combination therapy
regimens, the anthracycline antibiotic doxorubicin is the primary
route of treatment in a wide range of cancers, including breast
cancer. The cytotoxicity of doxorubicin is primarily mediated
by the inhibition of DNA topoisomerase II and subsequent gener-
ation of DNA double-strand breaks (Tewey et al., 1984). The
extent of DNA damage induced by doxorubicin exceeds the
DNA repair capacity of tumor cells, leading to cell cycle arrest
and cell death. Although breast tumors are often initially respon-
sive, the clinical efficacy of doxorubicin is severely limited by
intrinsic and acquired resistance. Characterization of mecha-
nisms that contribute to drug resistance and the identification
of novel strategies to circumvent doxorubicin resistance would
provide new and more effective therapies in the management
of breast cancer.1358 Cell Reports 11, 1358–1366, June 9, 2015 ª2015 The AuthorsThe phosphoinositide 3-kinase (PI3K) pathway plays a critical
role in virtually all aspects of tumor biology by regulating funda-
mental cellular functions, including cell proliferation and survival.
The PI3K pathway is frequently hyperactivated in breast cancer,
and numerous small molecule inhibitors have been developed to
specifically inactivate this pathway for cancer therapy (Baselga,
2011). Elevated PI3K pathway activity has been associated with
diminished sensitivity to conventional chemotherapy agents, and
theclass IPI3K inhibitorGDC-0941enhances theanti-tumoractiv-
ity ofdoxorubicin inbreastandovariancancercells thatdependon
PI3K for survival (Isakoff et al., 2005; Wallin et al., 2010). A major
effector of the PI3K pathway is the serine-threonine kinase Akt.
Phosphorylation at two sites, Thr308 and Ser473, increases the
enzymatic activity of Akt and leads to the phosphorylation of
numerous substrates containing the consensus RxRxxS/T motif.
Akt activation, in response to oncogenic PI3K pathway mutations
and in response to growth factor signaling, has been well docu-
mented.However, Akt also is regulated by thePI3K-related kinase
family member DNA-dependent protein kinase (DNA-PK), which
phosphorylates Akt at Ser473 in response to DNA damage
(Bozulic et al., 2008). The mechanisms by which Akt influences
cell survival following DNA damage are poorly understood.
Here we demonstrate that doxorubicin induces Akt activation
in breast cancer cell lines, and we show that PI3K and Akt in-
hibitors dramatically enhance the cytotoxicity of doxorubicin.
Mechanistically, we identify MERIT40 as an Akt substrate, and
we demonstrate that MERIT40 phosphorylation contributes to
the resolution of DNA damage following doxorubicin exposure.
We propose that the inhibition of MERIT40 phosphorylation
and disruption of DNA damage repair contribute to the efficacy
of combination therapy with PI3K/Akt inhibitors and doxorubicin.RESULTS
PI3K and Akt Inhibitors Sensitize Cells to
Doxorubicin-Induced Death
We first examined the ability of doxorubicin to induce Akt activa-
tion. Exposure of MCF10A breast epithelial cells to doxorubicin
results in elevated Akt phosphorylation at both Ser473 and
Thr308 in a time- and concentration-dependent manner (Figures
1A and 1B). Akt phosphorylation is accompanied by an increase
in phosphorylation of the Akt substrate PRAS40 and is also coin-
cident with phosphorylation of histone H2A.X, a marker of DNA
damage and genomic instability. Doxorubicin also enhances
Figure 1. Influence of Doxorubicin on Akt Activity and Contribution of PI3K/Akt Signaling toward Cell Survival following Doxorubicin
Exposure
(A and B) MCF10A cells were serum-starved and treated with (A) 2 mM doxorubicin over a 10-hr time course or (B) increasing concentrations of doxorubicin for
10 hr.
(C) T47D and SUM159 cells were serum-starved and treated with 0.5 mM doxorubicin for 24 hr.
(D) MCF10A cells were serum-starved and pre-treated with 2 mM BKM120, 2 mM MK2206, or 2 mM Nu7441 for 30 min before exposure to 2 mM doxorubicin for
10 hr.
(E) MCF10A cells were pre-treated with 1 mMMK2206, 1 mMBKM120, or 1 mMNu7441 for 24 hr before exposure to increasing concentrations of doxorubicin for
an additional 48 hr. Cell viability is expressed as a percentage of viability observed in untreated cells (t test; *p < 0.05, **p < 0.01, ***p < 0.001).
(F) MCF10A cells were pre-treated with 1 mMMK2206, 1 mMBKM120, or 1 mMNu7441 for 24 hr before the addition of 0.5 mM doxorubicin for an additional 24 hr.
(G) T47D, SUM159, andMCF7 cells were pre-treated with 1 mMMK2206 or 1 mMBKM120 for 24 hr before exposure to 0.5 mMdoxorubicin for an additional 48 hr.
Cell viability is expressed as a percentage of viability observed in untreated cells (t test; *p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 2. MERIT40 Is an Akt Substrate
(A) Domain structure of MERIT40 highlights the Akt consensus phosphorylation motif (24RPRTRS29), two TNKS-binding motifs (28RSNPEGAE35 and 48
RSEGEGE54), and a von Willebrand A domain (VWA).
(B) HA-Flag-MERIT40 and MERIT40 Ser29Ala were used as substrates in an in vitro kinase assay with recombinant active Akt1, Akt2, or Akt3.
(C) MCF10A cells were serum-starved and pre-treated with the indicated inhibitors for 30 min before stimulation with IGF-1 for 30 min.
(D) MCF10A cells were infected with empty vector or Akt small hairpin RNA (shRNA) constructs. Cells were serum-starved before stimulation with IGF-1 for
30 min.
(E) MCF10A cells were infected with vector control, PIK3CA wild-type (WT), PIK3CA E545K (EK), or PIK3CA H1047R (HR) constructs and serum-starved.
(legend continued on next page)
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Akt phosphorylation in T47D and SUM-159 breast cancer cells
(Figure 1C), despite the fact that both cell lines harbor activating
mutations in the PIK3CA gene that promote constitutive PI3K
pathway activity. The ability of doxorubicin to induce Akt activa-
tion is blocked by the DNA-PK inhibitor Nu7441, consistent
with the notion that DNA-PK is directly involved in activating
Akt downstream of DNA damage (Figure 1D). Interestingly, Akt
phosphorylation is also largely disrupted by the class I PI3K in-
hibitor BKM120, consistent with a recent study demonstrating
that doxorubicin induces activation of receptor tyrosine kinase
(RTK)/PI3K/Akt signaling (Bezler et al., 2012).
We next determined the contribution of Akt activity to cell sur-
vival following doxorubicin exposure. Single-agent doxorubicin
limits the viability of MCF10A cells in a concentration-dependent
manner (Figure 1E). However, the cytotoxicity of doxorubicin
is significantly enhanced when MCF10A cells are pre-treated
with Nu7441, BKM120, or MK2206, an allosteric pan-Akt inhibi-
tor, suggesting that DNA-PK/PI3K/Akt signaling contributes to
cell survival following DNA damage. Strikingly, Akt inhibition
with MK2206 is as effective at sensitizing cells to doxorubicin
as DNA-PK or PI3K inhibition, indicating that Akt plays a critical
role in regulating cell survival after DNA damage (Figure 1E).
It should be noted that the effect of single-agent Nu7441,
BKM120, or MK2206 on the viability of MCF10A cells is minimal.
Doxorubicin-induced cell death by apoptosis is exacerbated in
cells pre-treated with Nu7441, BKM120, or MK2206, as demon-
strated by enhanced cleavage of poly (ADP-ribose) polymerase
(PARP), a signature marker of apoptosis (Figure 1F). Inhibition
of DNA-PK, PI3K, or Akt also increases phosphorylation of his-
tone H2A.X following doxorubicin exposure, suggesting that
Akt directly contributes to DNA damage repair. Moreover, inhibi-
tion of PI3K or Akt sensitizes PI3Kmutant breast cancer cell lines
T47D, SUM159, and MCF7 to doxorubicin, and in all cases the
combination of Akt inhibitor and doxorubicin is as effective as
the combination of PI3K inhibitor plus doxorubicin (Figure 1G).
Taken together, these data demonstrate that Akt drives a sur-
vival pathway that promotes DNA repair and thereby desensi-
tizes cells to the toxicity of doxorubicin.
Akt Phosphorylates MERIT40 in Response to
Doxorubicin Exposure
As part of three distinct protein complexes, the tumor suppres-
sor breast cancer susceptibility gene 1 (BRCA1) plays a critical
role in regulating the cellular response to DNA damage. The
BRCA1-A complex, containing BRCA1, Abraxas, Rap80, BRE,
BRCC36, and MERIT40, forms at sites of DNA double-strand
breaks and contributes to the resolution of DNA damage (Feng
et al., 2009; Shao et al., 2009; Wang et al., 2009). A global phos-
phoproteomic screen identified that MERIT40 is phosphorylated
in a sequence that conforms to the optimal Akt consensus motif,
RxRxxS/T (Figure 2A; Moritz et al., 2010).
Using a phospho-MERIT40 Ser29-specific antibody, we found
that purified recombinant Akt1, Akt2, or Akt3 can directly phos-(F) MCF10A cells were transfected with vector control or myristoylated Akt allele
(G) MCF10A cells were serum-starved and exposed to 2 mM doxorubicin over a
(H) MCF10A cells were serum-starved and pre-treated with the indicated inhibito
(I) MCF10A cells were infected with empty vector or Akt shRNA constructs. Cells
Cphorylate MERIT40 at Ser29 (Figure 2B). Moreover, IGF-1 stim-
ulation promoted phosphorylation of MERIT40 and this was
blocked in cells pretreated with BKM120, MK2206, and the
mTORC1/2 inhibitor Torin1, but not the mTORC1 inhibitor rapa-
mycin, thereby implicating Akt as the kinase responsible for
MERIT40 phosphorylation at Ser29 (Figure 2C). Specific knock-
down of Akt isoforms also prevented MERIT40 phosphorylation
in response to IGF-1 stimulation (Figure 2D). Expression of
constitutively active PIK3CA alleles into MCF10A cells promoted
hyperactivation of Akt and enhanced MERIT40 phosphorylation
in the absence of growth factors (Figure 2E). Constitutively
active, myristoylated Akt1, Akt2, and Akt3 constructs also
were able to induce phosphorylation of MERIT40 in the absence
of growth factor (Figure 2F). Strikingly, doxorubicin also induced
rapid and sustained phosphorylation of MERIT40 at Ser29
(Figures 2G and S1), and this was blocked by Nu7441, Torin1,
and MK2206, but not rapamycin (Figure 2H). Consistent
with the notion that doxorubicin induces activation of RTK/
PI3K/Akt signaling, the EGFR inhibitor gefitinib and BKM120
blocked doxorubicin-induced MERIT40 phosphorylation. In
addition, specific knockdown of Akt isoforms completely in-
hibited MERIT40 phosphorylation and exacerbated histone
H2A.X phosphorylation in response to doxorubicin exposure
(Figure 2I). These data show that MERIT40 is an Akt substrate
phosphorylated in response to growth factor-induced Akt activa-
tion, hyperactivation of Akt via PI3K oncogenic mutations, and
downstream of DNA damage-induced activation of Akt.
MERIT40 Phosphorylation Promotes Assembly of the
BRCA1-A Complex
MERIT40 is an integral component of the nuclear BRCA1-A
complex and is required for BRCA1-A complex stability and
DNA damage resistance (Feng et al., 2009; Shao et al., 2009;
Wang et al., 2009). MERIT40 harbors two binding motifs for
the PARP family member tankyrase (TNKS) (Figure 2A; Guettler
et al., 2011). Interestingly, one TNKS-binding motif includes the
Ser29 residue. We therefore determined if TNKS is a compo-
nent of the BRCA1-A complex, and we examined the conse-
quence of phosphorylation on the ability of MERIT40 to interact
with TNKS. Previous studies have shown that MERIT40 is
required to maintain the stability of components of the
BRCA1-A complex (Hu et al., 2011). In addition to destabiliza-
tion of Rap80, Abraxas, BRE, and BRCC36, MERIT40 depletion
caused a dramatic reduction in TNKS expression (Figure 3A).
TNKS expression, as well as the expression of additional com-
ponents of the BRCA1-A complex, was fully rescued by re-
expression of either wild-type MERIT40 or a phosphorylation-
deficient MERIT40 Ser29Ala mutant (Figure 3A). This implies
that MERIT40 phosphorylation did not impact the ability of
MERIT40 to influence the stability of BRCA1-A complex com-
ponents or TNKS. These data, however, do suggest that
TNKS could represent a previously uncharacterized component
of the BRCA1-A complex.s (myrAkt1/2/3) and serum-starved.
10-hr time course. See also Figure S1.
rs for 30 min before exposure to 2 mM doxorubicin for 10 hr.
were serum-starved before exposure to 2 mM doxorubicin for 10 hr.
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Figure 3. Effect of MERIT40 Phosphorylation on Stability and Formation of the BRCA1-A Complex
(A) MCF10A cells were infected with empty vector or MERIT40 shRNA constructs and empty vector, WT MERIT40, or MERIT40 S29A mutant expression
constructs.
(B) MCF10A cells were serum-starved before exposure to 2 mM doxorubicin for 1 hr. Endogenous BRCA1 was immunoprecipitated from nuclear extracts and
co-immunoprecipitation with endogenous TNKS and Rap80 was monitored.
(C) HEK293T cells were transfected with WT or mutant MERIT40 constructs and a WT TNKS expression plasmid. HA-tagged MERIT40 was immunoprecipitated
from cells and co-immunoprecipitation of myc-tagged TNKS was monitored. Alternatively, myc-tagged TNKS was immunoprecipitated from cells and
co-immunoprecipitation of HA-tagged TNKS was monitored.
(D) MCF10A cells were infected with WT or mutant MERIT40 constructs. Cells were serum-starved and exposed to 2 mM doxorubicin for 1 hr. HA-tagged
MERIT40 was immunoprecipitated from cells and co-immunoprecipitation with endogenous TNKS and Rap80 was monitored.
(E) MCF10A cells were serum-starved and pre-treated with 2 mM MK2206 for 30 min before exposure to 2 mM doxorubicin for 1 hr. Endogenous MERIT40 was
immunoprecipitated from cells and co-immunoprecipitation with endogenous TNKS and Rap80 was monitored.
(F) MCF10A cells were serum-starved and treated with 2 mM doxorubicin for 1 hr or IGF-1 for 30 min. Endogenous MERIT40 was immunoprecipitated from cells
and co-immunoprecipitation with endogenous TNKS and Rap80 was monitored.
(G) T47D cells were infected with empty vector or aMERIT40 shRNA construct and empty vector, WTMERIT40, or MERIT40 S29Amutant expression constructs.
Cells were exposed to 0.5 mM doxorubicin for 1 hr, washed with PBS, and incubated in fresh media for an additional hour. Rap80 focus formation was monitored
by immunofluorescence.
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Consistent with this model, co-immunoprecipitation experi-
ments revealed that endogenous TNKS interacts with endoge-
nous BRCA1, and this interaction was enhanced following
doxorubicin exposure (Figure 3B). Co-immunoprecipitation ex-
periments also showed that MERIT40 interacts with TNKS (Fig-
ure 3C). However, whereas wild-type MERIT40 binds TNKS with
high affinity, MERIT40 Ser29Ala showed dramatically reduced
binding to TNKS (Figure 3C). In cells exposed to doxorubicin,
an increase in the interaction of wild-type MERIT40 with endoge-
nous Rap80 and TNKS was observed (Figure 3D). By contrast,
doxorubicin did not stimulate the association of either Rap80 or
TNKS with MERIT40 Ser29Ala, indicating that phosphorylation
ofMERIT40 promotes the association of BRCA1-A complex com-
ponents in response toDNA damage. This conclusion is also sup-
portedby theobservation thatdoxorubicin triggeredan increase in
the association of endogenous TNKS and Rap80 with endoge-
nous MERIT40 (Figure 3E). Strikingly, the interaction of MERIT40
with TNKS and Rap80 in response to DNA damagewas disrupted
by the Akt inhibitor MK2206, indicating that MERIT40 phosphory-
lation was required to enhance the association of BRCA1-A com-
plex components following DNA damage (Figure 3E). Importantly,
a phosphorylation-dependent increase in the association of
BRCA1-A complex components was not observed in cells stimu-
lated with IGF-1, indicating that BRCA1-A complex formation
specifically requires a DNA damage signal in addition to Akt-
dependent phosphorylation of MERIT40 (Figure 3F). Consistent
with previous studies, MERIT40 depletion compromised Rap80
focus formation upon DNA damage (Figure 3E; Feng et al.,
2009). Rap80 focus formation was completely rescued by re-
expression of wild-type MERIT40, but not by phosphorylation-
deficient MERIT40 Ser29Ala. These data demonstrate that
MERIT40 phosphorylation plays an integral role in assembly of
the BRCA1-A complex following doxorubicin exposure.
MERIT40 Phosphorylation Contributes to the Resolution
of DNA Damage
To further evaluate the functional significance of MERIT40 phos-
phorylation by Akt, we investigated the ability of MERIT40 to in-
fluence DNA damage repair. Depletion of MERIT40 from T47D
cells dramatically enhanced doxorubicin-induced DNA damage,
as revealed by an increase in histone H2A.X phosphorylation
(Figure 4A) and phospho-H2A.X focus formation (Figures 4B
and 4C). This response was rescued by re-expression of wild-
type MERIT40, but not MERIT40 Ser29Ala. These data demon-
strate that MERIT40 phosphorylation at Ser29 is required for
the resolution of doxorubicin-induced DNA damage. In addition,
MERIT40 depletion dramatically enhanced spontaneous DNA
damage in MCF10A cells, and this could be rescued by re-
expression of wild-type MERIT40, but again not by MERIT40
Ser29Ala (Figure S2). Importantly, MERIT40 depletion sensitized
cells to doxorubicin, and this response was rescued by re-
expression of wild-type MERIT40, but not MERIT40 Ser29Ala
(Figures 4D and 4E). Taken together, these data demonstrate
that Akt-dependent phosphorylation of MERIT40 promotes
DNA repair and that MERIT40 phosphorylation contributes to
cell survival following doxorubicin exposure.
Elevated MERIT40 expression has been identified in epithelial
ovarian cancer, and SNPs within the MERIT40 gene are associ-Cated with breast cancer risk (Antoniou et al., 2010; Bolton et al.,
2010). However, the expression of MERIT40 and phospho-
MERIT40 in humanbreast tumors has not been examined. Tissue
microarrays containing cores of invasive breast cancer tissue ob-
tained from archival pathology specimens were used to examine
expression ofMERIT40 andphospho-MERIT40 by immunohisto-
chemistry (IHC). This analysis revealed, in a subset of cases,
strong phospho-MERIT40 staining that was present in both the
nuclei and cytoplasm (Figure 4F, positive/strong). A subset of
cases showed no phospho-MERIT40 staining (Figure 4F, nega-
tive/weak). Overall, the total MERIT40 staining showed more in-
termediate staining with fewer strongly positive cases (Figure 4F,
intermediate).Wealso usedcomputational analysis to assess the
association of phospho-MERIT40 nuclear staining with breast
cancer subtypes. This analysis revealed a strong, statistically sig-
nificant association of nuclear phospho-MERIT40 with estrogen
receptor (ER) status (p = 3.3 3 105) (Figure 4G).
DISCUSSION
Resistance to cytotoxic chemotherapy agents is a common phe-
nomenon in breast cancer that has a drastic impact on patient
survival. This underscores the need to identify strategies to over-
come drug resistance. One approach that has been favored in
recent years is the development of drug regimens combining
cytotoxic chemotherapy with molecularly targeted drugs that
inhibit signaling cascades critical to breast cancer survival and
progression. The PI3K/Akt pathway is hyperactive in more than
70% of breast tumors and is critical for tumor progression and
resistance to anti-cancer drugs (Courtney et al., 2010). In addi-
tion, as highlighted in this study, an undesirable response to
chemotherapy exposure is activation of PI3K/Akt signaling.
Rationally designed small molecule inhibitors that target either
PI3K or Akt recently have been developed and are currently in
phase I or II clinical trials (Dienstmann et al., 2014). Unfortunately,
modest anti-tumor responses have been reported following PI3K
and Akt inhibitor monotherapy and substantial tumor regression
is rarely observed (Rodon et al., 2013). In an attempt to improve
response rates to PI3K and Akt inhibitors, clinical trials that incor-
porate these inhibitors and traditional chemotherapeutic drugs
are now in progress (Paplomata and O’Regan, 2014). Our study
provides evidence that PI3K and Akt inhibitors dramatically
sensitize breast cancer cells to the DNA-damaging chemo-
therapy agent doxorubicin. The frequency of PI3K pathway alter-
ations in breast cancer combined with the ability of doxorubicin
to induce PI3K/Akt activity provides rationale to assess combi-
nation therapy with doxorubicin and PI3K inhibitors in the clinic.
In chemotherapy-sensitive cancer cells, DNA damage result-
ing from doxorubicin exposure leads to cell death via the induc-
tion of apoptosis. The ability of the PI3K/Akt pathway to promote
cell survival has been widely reported and a number of sub-
strates that contribute to the inhibition of apoptosis have been
identified (Manning and Cantley, 2007). Although it is well estab-
lished that Akt activity promotes resistance to DNA damage, the
substrates that directly impact DNA damage repair are poorly
characterized (Xu et al., 2012). Our study identifies MERIT40, a
component of the BRCA1-A DNA damage repair complex, as
an Akt substrate that directly influences the cellular responseell Reports 11, 1358–1366, June 9, 2015 ª2015 The Authors 1363
Figure 4. Contribution ofMERIT40 Phosphorylation toward theResolution of DNADamage andCell Survival followingDoxorubicin Exposure
and Detection of Phospho-MERIT40 in Human Breast Tumors
(A) T47D cells were infected with empty vector or aMERIT40 shRNA construct and empty vector, WTMERIT40, or MERIT40 S29Amutant expression constructs.
Cells were exposed to 0.5 mM doxorubicin for 1 hr, washed with PBS, and incubated in fresh media for an additional 6 hr. See also Figure S2.
(B) T47D cells were infected with empty vector or aMERIT40 shRNA construct and empty vector, WTMERIT40, or MERIT40 S29Amutant expression constructs.
Cells were exposed to 0.5 mM doxorubicin for 1 hr, washed with PBS, and incubated in fresh media for an additional 6 hr. Phosphorylation of histone H2A.X was
monitored by immunofluorescence.
(C) The percentage of cells with nuclear p-Histone H2A.X foci was quantified by counting 200 cells in each treatment condition (t test, **p < 0.01).
(D) MCF10A cells were transfected with control or MERIT40 small interfering RNA (siRNA) constructs and empty vector, WT MERIT40, or MERIT40 S29A mutant
expression constructs. Cells were exposed to 0.2 mM doxorubicin for 48 hr. Cell viability is expressed as a percentage of viability observed in untreated cells
(t test, *p < 0.05).
(E) MCF10A cells were transfected with control or MERIT40 siRNA constructs and empty vector, WTMERIT40, or MERIT40 S29A mutant expression constructs.
Cells were exposed to 0.2 mM doxorubicin for 24 hr.
(F) Detection of p-MERIT40 and MERIT40 in invasive breast tumor tissue samples by IHC is shown.
(G) Relationship between p-MERIT40 IHC staining in human breast tumor samples and ER status is shown.
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to DNA damage. Specifically, we show that MERIT40 phosphor-
ylation at Ser29 facilitates the association of MERIT40 with the
ubiquitin-binding protein Rap80. Furthermore, we show that
MERIT40 phosphorylation promotes nuclear Rap80 focus for-
mation. Rap80 is a critical scaffold protein in the BRCA1-A com-
plex required to relocate and target the remaining subunits of the
BRCA1-A complex to sites of DNA damage (Bian et al., 2012;
Kim et al., 2007; Sobhian et al., 2007; Wang et al., 2007; Wu
et al., 2012). Future studies to investigate the effect of MERIT40
phosphorylation in facilitating the association of MERIT40 with
additional components of the BRCA1-A complex are warranted.
Importantly, we also demonstrate thatMERIT40 phosphorylation
promotes DNA damage repair and contributes to cell survival
following doxorubicin exposure. We therefore propose that
inhibition of MERIT40 phosphorylation and disruption of DNA
damage repair contributes to the efficacy of combination therapy
with PI3K/Akt inhibitors and doxorubicin.
Our study also identifies the PARP family member TNKS as a
component of the BRCA1-A complex. We demonstrate that
MERIT40 interacts with TNKS and furthermore that MERIT40
phosphorylation promotes the association of MERIT40 with
TNKS. TNKS previously has been implicated in the regulation
of DNA damage repair and has been shown to influence stability
of the catalytic subunit of DNA-PK via poly-ADP-ribosylation
(PARsylation) (Dregalla et al., 2010). In addition, PARP1 has
been shown to PARsylate BRCA1 and thereby maintain stability
of the BRCA1-A complex (Hu et al., 2014). The ability of TNKS
to influence DNA damage repair via PARsylation of DNA-PK,
BRCA1, or additional BRCA1-A complex components clearly
merits further investigation. In addition, it will be interesting to
evaluate the contribution of MERIT40 phosphorylation to DNA
damage-induced protein PARsylation.
Molecular markers that might predict the efficacy of combina-
tion therapy with PI3K/Akt pathway inhibitors and cytotoxic
agents, like doxorubicin, are lacking. Another interesting obser-
vation arising in this study is that phospho-MERIT40 staining is
associated with ER status in invasive breast tumor tissue sam-
ples. It should be noted that activating mutations in the PIK3CA
gene occur in a significant proportion of ER-positive breast can-
cers (Cancer Genome Atlas Network, 2012). Our results suggest
that MERIT40 phosphorylation could be used as a biomarker in
ER-positive breast cancer patients to predict sensitivity to tradi-
tional cytotoxic chemotherapy agents, and they indicate that pa-
tients with high levels of phospho-MERIT40 would likely benefit
from combination therapy with Akt inhibitors and doxorubicin.
In summary, our study identifies a mechanism by which the
PI3K/Akt pathway mediates DNA repair in response to chemo-
therapy exposure, and it indicates that combining PI3K/Akt in-
hibitors with doxorubicin may constitute a successful strategy
to overcome chemotherapy resistance in breast cancer, at least
in part by disrupting the phosphorylation of MERIT40.EXPERIMENTAL PROCEDURES
Immunoblotting
Cells were washed with PBS and lysed in RIPA buffer. Lysates were resolved
by SDS-PAGE and transferred electrophoretically to nitrocellulose membrane
(Bio-Rad) followed by immunoblotting.CSulforhodamine B Assay
Cell viability wasmonitored using the sulforhodamine B (SRB) assay. Adherent
cells were fixed by the addition of 12.5% (w/v) trichloroacetic acid and incuba-
tion at 4C for 1 hr. Wells were washed with water and cells were stained by the
addition of SRB solution (0.5% [w/v] SRB and 1% acetic acid). Wells were
washed twice with 1% acetic acid and allowed to dry at room temperature.
SRB was solubilized with 10 mmol/l Tris (pH 10.5) and absorbance at
510 nm was measured.
In Vitro Kinase Assay
MSCV-HA-Flag-MERIT40 or MSCV-HA-Flag-MERIT40 Ser29Ala MERIT40
was immunoprecipitated from cell extracts and incubated with 500 ng of
recombinant Akt1, Akt2, or Akt3 (Sigma-Aldrich) in a kinase buffer contain-
ing 250 mmol/l cold ATP for 1 hr at 30C. Eluates were resolved by SDS-
PAGE.
Immunoprecipitation
Nuclear extracts were prepared by high salt extraction. For whole-cell lysate
preparation, cells were washed with PBS and lysed in EBC lysis buffer.
Lysates were incubated with 1–2 mg antibody overnight at 4C followed by
incubation with protein A/G Sepharose beads (Amersham Biosciences). Im-
mune complexes were washed with NETN buffer and eluted by incubation
for 5 min at 95C in SDS-PAGE sample buffer. Eluates were resolved by
SDS-PAGE.
Immunofluorescence
Cells plated on coverslips were fixed with 2% paraformaldehyde for 10 min,
permeabilized with 0.5% Triton X-100, and blocked with 1% BSA in
20 mmol/l Tris-HCl (pH 7.5) for 20 min. Coverslips were then incubated with
the appropriate antibodies. After washing twice with PBS, coverslips were
mounted with Prolong Gold antifade reagent containing DAPI (Life Technolo-
gies). Images of cells were acquired using a fluorescence microscope (Nikon
Eclipse Ti) and digital image analysis software (NIS-Elements, Nikon).
Tissue Microarrays and Image Analysis of Immunohistochemistry
Two tissue microarrays containing breast tissue specimens, from the archives
of the Department of Pathology at the BIDMC, were constructed as previously
described (Elloul et al., 2014). Immunohistochemistry staining was done for to-
tal MERIT40 and p-MERIT40 Ser29. Computational image analysis of protein
expression was performed using Definiens TissueStudio 3.6.1 to yield the in-
tensity of nuclear expression of p-MERIT40 Ser 29 andMERIT 40 in the cancer
epithelium. The proportion of positively staining epithelial nuclei was recorded
for each core and reported as the Nuclear Positive Index.
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